Cambodia Pharmaceuticals & Healthcare Report

Providing expert analysis, independent forecasts and competitive intelligence on the pharmaceuticals and healthcare industry.

Report includes: BMI Industry View, Industry SWOT Analysis, Industry Forecasts, BMI's Pharmaceuticals and Healthcare Risk Reward Index, Market Summary, Economic Forecasts, Company Profiles and Competitive Landscape.

Why you should buy this report

  • Benefit from the latest market opportunities
  • Understand the threats to your operations and investments and protect your company against future risks
  • Gain insight on emerging trends that could support, strengthen or disrupt your activities in the market
  • Get a full view of the competitive landscape to assess your market position
×

Sign up to download the Cambodia Pharmaceuticals & Healthcare Report

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

You will shortly receive your free executive summary by email.

Cambodia Pharmaceuticals & Healthcare Report
Product Price
$1,295.00

BMI View: While the underdeveloped nature of its pharmaceutical and health care sector will bring about commercial benefits for foreign investors, competition from relatively low risk and higher rewards markets such as Vietnam mean s that Cambodia will remain low on investors '' priority list.

Headline Expenditure Projections

  • Pharmaceuticals: KHR910.8bn (USD228mn) in 2014 to KHR1,008.1bn (USD252mn) in 2015; +10.7% in local currency terms and US dollar terms. Forecast remains unchanged from previous quarter.

  • Healthcare: KHR5,119.8bn (USD1.3mn) in 2014 to KHR5,676.2bn (USD1.4mn) in 2015; +10.9% in local currency terms and US dollar terms. Forecast unchanged from previous quarter.

Headline Pharmaceuticals & Healthcare Forecasts (Cambodia 2013-2019)
2013 2014 2015f 2016f 2017f 2018f 2019f
f = BMI forecast. Source: National Sources, BMI
Pharmaceutical sales, USDbn 0.204 0.228 0.252 0.278 0.306 0.336 0.369
Pharmaceutical sales, % of GDP 1.34 1.36 1.38 1.38 1.38 1.37 1.36
Pharmaceutical sales, % of health expenditure 17.8 17.8 17.8 17.7 17.6 17.4 17.2
Health spending, USDbn 1.149 1.280 1.419 1.573 1.744 1.933 2.142

Risk/Reward Index

Cambodia's Pharmaceutical Risk/Reward Index score for Q415 is 33.1 out of the maximum 100. The country scored below average for almost all indicators and sub-indicators including overall market expenditure, sector value growth and pensionable population. Consequently, with this low score, Cambodia ranks second-to-last out of the 19 key markets in Asia Pacific, ahead of Myanmar. Cambodia mainly suffers from low per capita consumption, stemming from low wages, the absence of a national health insurance scheme and the wider lack of government financing in the country, poor intellectual property protection and cumbersome bureaucracy.

Key Trends And Developments

  • In November 2015, Cambodia and Russia signed ten agreements covering various areas such as healthcare and nuclear energy. These agreements are expected to promote cooperation and bilateral ties.

  • In the same month, trade unions proposed to have a new committee to monitor the country's fund for injured workers, pension programs for civil servants and healthcare for the poor so as to improve coverage.

BMI Economic View

The conclusion of the Trans-Pacific Partnership (TPP) agreement will have mixed effects on the Cambodian economy. On the one hand, Vietnam's entry into the pact and the elimination of tariffs in its exports and textiles sectors will undermine Cambodia's export competitiveness in this area. On the other hand, Vietnam is likely to benefit in terms of low-tech manufacturing exports, providing Cambodia with an opportunity to piggyback on growth in areas such as auto parts assembly as ASEAN economic integration increases under the ASEAN Economic Community.

BMI Political View

The arrest warrant for opposition leader Sam Rainsy on November 13 confirms our view that the political truce known as the 'culture of dialogue' between the government and the opposition is over. This raises the prospect of renewed street demonstrations and poses possibly the largest risk to Cambodia's business environment since the aftermath of the 2013 election.

BMI Industry View
7
SWOT
9
Industry Forecast
11
Pharmaceutical Market Forecast
11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Cambodia 2011-2019)
12
Healthcare Market Forecast
13
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Cambodia 2011-2019)
14
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Cambodia 2011-2019)
14
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Cambodia 2011-2019)
15
Pharmaceutical Trade Forecast
16
Table: Pharmaceutical Trade Data And Forecasts (Cambodia 2013-2019)
18
Key Risks To BMI's Forecast Scenario
18
Macroeconomic Forecasts
19
Economic Analysis
19
Industry Risk Reward Index
21
Asia Pacific Risk/Reward Index
21
Cambodia Risk/Reward Index
27
Rewards
27
Risks
27
Market Overview
29
Industry Trends And Developments
30
Epidemiology
30
Healthcare Sector
32
Health Insurance
33
Research & Development
34
Clinical Trials
35
Regulatory Development
36
Regulatory Regime
36
Intellectual Property Issues
36
Counterfeit Medicines
37
Pricing And Reimbursement
39
Competitive Landscape
40
Pharmaceutical Sector
40
Company Developments
42
Pharmaceutical Wholesale
43
Pharmaceutical Retail
43
Company Profile
45
Cambodia Pharmaceutical Enterprise
45
Pfizer
47
PharmaProduct Manufacturing (PPM)
49
Sanofi
52
Demographic Forecast
55
Table: Population Headline Indicators (Cambodia 1990-2025)
56
Table: Key Population Ratios (Cambodia 1990-2025)
56
Table: Urban/Rural Population & Life Expectancy (Cambodia 1990-2025)
57
Table: Population By Age Group (Cambodia 1990-2025)
57
Table: Population By Age Group % (Cambodia 1990-2025)
58
Glossary
60
Methodology
62
Pharmaceutical Expenditure Forecast Model
62
Healthcare Expenditure Forecast Model
62
Notes On Methodology
63
Risk/Reward Index Methodology
64
Index Overview
65
Table: Pharmaceutical Risk/Reward Index Indicators
65
Indicator Weightings
66

The Cambodia Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Cambodia Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Cambodia pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Cambodia, to test other views - a key input for successful budgeting and strategic business planning in the Cambodian pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Cambodian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Cambodia.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.